2020 Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection

M Buti, MD
Hospital Universitario Valle Hebrón and CIBER EHD del Instituto Carlos III
Barcelona Spain
Disclosures

• Speaker and Advisor
  Abbvie and Gilead Sciences

• Advisor
  Assembly, GSK and Altoinmune
CLINICAL PRACTICE GUIDELINES

Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020)☆

Manuel Rodríguez, Maria Buti, Rafael Esteban, Sabela Lens, Martín Prieto, Emilio Suárez, Javier García-Samaniego.
Why to update AEEH Hepatitis B Guidelines?

• 2012 AEEH consensus document on the treatment of hepatitis B virus Hígado
• Changes in the epidemiology and the understanding of the natural history of hepatitis B,
• Changes in the diagnostic methods and treatment indications
• No major advances in the treatment of chronic hepatitis B

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Methodology

• An expert panel to review and update the document.
• The final version was approved by the Governing Board.
• The recommendations were based on the available scientific evidence. If information was insufficient or non-existent, recommendations were based on the opinions and personal experience of the experts themselves.
• The recommendations were classified according the quality of the scientific evidence into three levels: high (A), moderate (B) or low (C).
• Two levels of recommendation: strong (1) or weak (2).
Hepatitis B Epidemiology in Spain

- HBsAg in the general population from 2% to 7% (Intermediate prevalence)
- In 1990 Hepatitis B vaccine was added to the National Health Programme
- Vaccine coverage above 95%
- Current prevalence of HBsAg around 0.5%-0.8% (low endemicity)
- Incidence from 2008 until now stable, 1.27 to 1.65 cases per 100,000 population

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Hepatitis B was made a notifiable disease in Spain in 1995. Cases are declared individually on a weekly basis, with an epidemiological survey. Case definition included probable and confirmed cases.
Factors associated with HBsAg decline

• Hepatitis B Vaccination
• Systematic control of blood donations
• Screening of pregnant women
• Programs to avoid high risk behaviors: Harm reduction programs, condoms, tattoos and body piercing under unhygienic conditions

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Recommendations:

- As it is a notifiable disease, cases of hepatitis B (probable or confirmed) should be sent to the Centro Nacional de Epidemiología (A1).
- Most people infected with HBV will not develop symptoms during the course of the infection, so serological screening is recommended in at-risk populations (A1).
Characteristics of the phases of chronic hepatitis B virus infection

<table>
<thead>
<tr>
<th>HBeAg-positive</th>
<th>HBeAg-negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chronic infection</td>
</tr>
<tr>
<td>Prior terminology</td>
<td>Immune tolerant</td>
</tr>
<tr>
<td>qHBsAg (IU/ml)</td>
<td>Very high</td>
</tr>
<tr>
<td>HBV DNA (IU/ml)</td>
<td>&gt;10 million</td>
</tr>
<tr>
<td>ALT (IU/l)</td>
<td>Normal</td>
</tr>
<tr>
<td>Histology</td>
<td>Normal/minimal changes</td>
</tr>
</tbody>
</table>

$^a$ Generally <1,000 IU/ml.

$^b$ Some HBeAg-negative patients with chronic infection have persistently normal ALT levels with HBV DNA levels in the range 2,000-20,000 IU/ml and a good long-term prognosis.

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Recommendations:

- An accurate diagnosis is necessary to determine the current stage of the natural history of liver disease, based on the determination of HBeAg, anti-HBe, HBV DNA and ALT (A1).
- The determination of qHBsAg is useful for the diagnosis of HBeAg-negative chronic infection (B1).
- Liver elastography is the non-invasive method of choice for assessing liver injury due to its greater diagnostic precision, especially for ruling out advanced fibrosis (A1).
- Biomarkers seem to have lower diagnostic precision, so further studies are needed to expand their use (B1).
- Ultrasound is useful for diagnosing liver cirrhosis and HCC (A1).
- Liver biopsy is indicated in patients with associated liver disease and in whom the elastography value is in the grey area (B1).
Recommendations

1. In individuals with chronic hepatitis B, treatment is indicated if ALT levels are elevated, HBV DNA levels are higher than 2,000 IU/ml and/or there is at least moderate necroinflammatory activity and/or fibrosis (A1).

2. Patients with compensated liver cirrhosis should be treated if HBV DNA is detectable, even if ALT levels are normal (A1).

3. Patients with decompensated cirrhosis should be treated without delay with potent nucleos(t)ide analogues, regardless of HBV DNA and ALT levels (A1).

4. Patients with a family history of HCC or extrahepatic manifestations may be treated even if they do not meet all the criteria (B2).

5. Patients with chronic hepatitis B not receiving treatment should be followed up every six months (A1).
## Treatment recommendations: Advantages and Disadvantages

<table>
<thead>
<tr>
<th>Treatment duration</th>
<th>Nucleos(t)ide analogues</th>
<th>Pegylated interferon</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Indefinite</td>
<td>Limited (12 months)</td>
</tr>
<tr>
<td>Route of administration</td>
<td>Oral</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Antiviral activity</td>
<td>Potent</td>
<td>Modest</td>
</tr>
<tr>
<td>Development of resistance</td>
<td>Extremely uncommon</td>
<td>Never</td>
</tr>
<tr>
<td>Loss of HBeAg and HBsAg</td>
<td>Uncommon</td>
<td>Modest, genotype-dependent</td>
</tr>
<tr>
<td>Adverse effects</td>
<td>Rare</td>
<td>Common</td>
</tr>
<tr>
<td>Safety in pregnancy</td>
<td>TDF: class B</td>
<td>Class C</td>
</tr>
<tr>
<td>Contraindications</td>
<td>None</td>
<td>Common</td>
</tr>
</tbody>
</table>

### Recommendations

1. **Initial treatment of chronic hepatitis B**, whether HBeAg-positive or HBeAg-negative, is based on single-drug therapy with a nucleos(t)ide analogue or PEG-IFN (A1).

2. The choice of one or the other strategy will depend on the stage of liver fibrosis, virological factors, the patient’s comorbidity profile and the patient’s own preferences (B1).

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Choice of analogue in special situations.

<table>
<thead>
<tr>
<th>Situation</th>
<th>Preference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKD stage &gt;2 (eGFR &lt;60 ml/min)</td>
<td>ETV (with dose adjustment) or TAF</td>
</tr>
<tr>
<td>Predisposing factors of CKD</td>
<td>ETV or TAF</td>
</tr>
<tr>
<td>Poorly controlled diabetes or hypertension</td>
<td></td>
</tr>
<tr>
<td>Use of potentially nephrotoxic drugs</td>
<td></td>
</tr>
<tr>
<td>Proteinuria</td>
<td></td>
</tr>
<tr>
<td>Active glomerulonephritis</td>
<td></td>
</tr>
<tr>
<td>Age &gt;60 years</td>
<td></td>
</tr>
<tr>
<td>Osteoporosis or corticosteroid therapy</td>
<td>ETV or TAF</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>TDF</td>
</tr>
<tr>
<td>Previous treatment with nucleos(t)ide analogues</td>
<td>TDF or TAF</td>
</tr>
<tr>
<td>Decompensated cirrhosis</td>
<td>ETV or TAF</td>
</tr>
<tr>
<td>HIV co-infection</td>
<td>TDF or TAF</td>
</tr>
</tbody>
</table>

CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate.

TDF, TAF, Entecavir and PegINF are approved and fully reimbursed except TAF, only reimbursed in patients with renal disease

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Recommendation of therapy duration with PEG-IFN

- Duration of PEG-IFN therapy is 48 weeks (B1)

- In HBeAg+ve patients with genotype A or D who, after 12 wks of PegIFN, have qHBsAg >20,000 IU/ml and the absence of a decrease compared to baseline, treatment can be stopped due to lack of efficacy (B1)

- In HBeAg-ve patients with genotype D infection who, after 12 wks of treatment, show the absence of a decrease in qHBsAg levels combined with no decrease in HBV DNA by< 2log both compared to baseline, treatment can be stopped due to lack of efficacy (B1).

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Recommendation therapy duration with Nucleos(t)ide Analogues

- Initially, the duration of treatment with a nucleos(t)ide analogue is indefinite. The safest strategy for stopping treatment is based on doing so once negative results for HBsAg have been achieved; therefore, treatment should be stopped once that goal has been reached and confirmed to have been reached (B1).

- In patients with HBeAg-positive chronic hepatitis, treatment can be stopped before negative results for HBsAg have been achieved in case of virological response and HBeAg seroconversion confirmed by two determinations three to six months apart after at least 12 months of consolidation therapy (B2).

- In patients with HBeAg-negative chronic hepatitis, stopping treatment before achieving negative results for HBsAg can be considered in patients without advanced fibrosis or cirrhosis at the start of treatment, with a sustained virological response for at least three years, once HBsAg levels <100 IU/ml have been achieved, provided they are willing to be closely monitored after discontinuation (C2).

- In any event, treatment should not be stopped before the infection is resolved in patients with liver cirrhosis diagnosed at the start of or during treatment, patients with systemic manifestations of the disease, patients on immunosuppressant treatment and patients not willing to undergo close monitoring (B1).

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Recommendations for Nucleoside analogues

• In any situation involving the absence of virological response to analogue therapy, the degree of adherence to treatment should be investigated (B1).

• In patients with partial virological response at week 48, if HBV DNA levels continue to decline, the same analogue should be continued; if they do not, switching to another analogue or combination therapy with ETV + TDF or TAF should be considered (B2).

• In patients who develop resistance to ETV, switching to TDF or TAF is recommended (A1).

• In the hypothetical case of resistance to TDF or TAF, switching to ETV or add ETV to TDF or TAF in case of a history of resistance to LAM.

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Monitoring during therapy

• Periodic testing should be done to check ALT, HBV DNA and qHBsAg levels

• In patients treated with nucleos(t)ide analogues, kidney function and serum phosphate levels should be periodically monitored, while in those treated with PEG-IFN, tests should include a complete blood count and TSH (A1)
Recommendations for Patients with Decompensated Cirrhosis

• **Patients with decompensated cirrhosis** should be treated without delay with an analogue with a high genetic barrier to resistance, regardless of their HBV DNA levels (A1)

• These patients on analogue therapy should be closely monitored for treatment-related adverse effects such as kidney failure and lactic acidosis (A1)

• Patients with decompensated cirrhosis should be referred for assessment for liver transplantation if they are potential candidates, without waiting for HBV DNA levels to become undetectable (A1)

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Algorithm for prophylaxis for hepatitis B recurrence in de novo patients.

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Recommendations for HBV Liver Transplant

• All patients on the liver transplant waiting list due to HBV-related liver disease should be treated with an analogue with a high genetic barrier to resistance (A1)

• Prophylaxis for post-liver transplant hepatitis B recurrence should be based on indefinite administration of ETV or TDF/TAF (A1)

• A personalised approach to HBIG use is recommended based on risk of post-liver transplant HBV infection recurrence (A1)

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Recommendations for HBV Coinfected Patients

• HIV and HBV
The indications for treatment of hepatitis B in HIV+ve patients are the same as in non-HIV-positive.
All co-infected patients should treated with combinations based on TDF/TAF with LAM/emtricitabine, regardless of their CD4+ lymphocyte count (A1)

• HDV and HBV
PEG-IFN for 48 wks is the recommended for compensated chronic hepatitis D and achieves virological response in 25% of patients
Oral antivirals for HBV are not effective for HDV, but should be used if there is active HBV replication (HBV DNA >2,000 IU/ml in patients without cirrhosis or any HBV DNA levels in patients with cirrhosis) (A1).

• HCV and HBV
In patients co-infected with hepatitis B and C, there is a risk of reactivation of HBV during or after treatment with direct antivirals. HBV DNA levels should be closely monitored in HBsAg+ve patients being treated for hepatitis C, treatment should be started with nucleos(t)ide analogues (ETV or TDF/TAF) if it is indicated and in the remaining patients prophylaxis should be considered
Recommendations related HCC

- Patients with cirrhosis due to HBV should have ultrasound screening for HCC every six months (A1)

- In patients without cirrhosis but have a family history of HCC or are from an African or Asian country and >40 yrs (if male) or >50 yrs (if female), especially in case of vertical transmission or genotype C infection, ultrasound screening for HCC every 6 months is recommended (B1)

- In patients treated with ETV or TDF, it is recommended that the PAGE-B score be calculated at the start of treatment. High-risk patients (score ≥18 points) should be included in a programme of screening for HCC every six months; screening may be considered for moderate-risk patients (10-17 points) (B2)

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Hepatitis B pregnancy and children

• In pregnant women, treatment decision-making must weigh the severity of the disease and the risk of perinatal transmission. Besides, active and passive immunoprophylaxis (vaccine+HBIG) in all newborns, in women with high viraemia (>200,000 IU/ml) TDF is recommended at wks 24-28 of pregnancy.

In women already being treated with analogues, the medication should not be discontinued, but they should be switched to TDF if they were receiving another antiviral (A1).

• The incidence of HBV infection in children has decreased significantly in recent years (A1). In the few cases in which treatment is indicated, ETV and TDF are the drugs of choice, as in the adult population (B1).

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
Recommendations: Hepatitis B and Immunosuppression

- All candidates for chemotherapy and immunosuppressant or biologic therapy should undergo screening for HBV (A1)

- Antiviral prophylaxis is recommended in HBsAg+ve patients at moderate/high risk of reactivation and in HBsAg-ve, anti-HBc+ve patients at high risk of reactivation. For HBsAg-ve, antiHBc+ve patients at moderate/low risk, monitoring during and for 6 months after immunosuppression is recommended (B1)

- The recommended drugs in antiviral prophylaxis are ETV, TDF and TAF (A2)

- Antiviral prophylaxis should preferably be started 2 wks prior immunosuppression, especially in cases with detectable HBV DNA, and should be continued for 12 mo (18 mo for rituximab or other anti-CD20 antibodies) after therapy discontinuation (B1)

Rodriguez M, Buti M et al. Gastroenterol Hepatol 2020;43:559-587
<table>
<thead>
<tr>
<th>Type of immunosuppressant treatment</th>
<th>HBsAg positive</th>
<th>HBsAg negative and anti-HBc positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-cell–depleting therapies (e.g. rituximab, natalizumab or alemtuzumab)</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Immunosuppression associated with bone marrow transplantation</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Potent TNF (inhibitors (e.g. infliximab, adalimumab, certolizumab or golimumab)</td>
<td>Moderate/high</td>
<td>Low/moderate</td>
</tr>
<tr>
<td>Anthracycline derivatives (e.g. doxorubicin)</td>
<td>High</td>
<td>Low/moderate</td>
</tr>
<tr>
<td>Local treatment of HCC (TACE)</td>
<td>High</td>
<td>Low/moderate</td>
</tr>
<tr>
<td>Systemic chemotherapy or cytokine or integrin inhibitors (e.g. abatacept, ustekinumab, natalizumab</td>
<td>Moderate</td>
<td>Low/moderate</td>
</tr>
<tr>
<td>Cyclophilin inhibitors (e.g. ciclosporin)</td>
<td>Moderate</td>
<td>Low/moderate</td>
</tr>
<tr>
<td>Tyrosine kinase inhibitors (e.g. imatinib)</td>
<td>Moderate</td>
<td>Low/moderate</td>
</tr>
<tr>
<td>Proteasome inhibitors (e.g. bortezomib)</td>
<td>Moderate</td>
<td>Low/moderate</td>
</tr>
<tr>
<td>Histone deacetylase inhibitors (e.g. romidepsin)</td>
<td>Moderate</td>
<td>Low/moderate</td>
</tr>
<tr>
<td>Less potent TNF- (inhibitors (e.g. etanercept)</td>
<td>Moderate</td>
<td>Low</td>
</tr>
<tr>
<td>Prednisone (or equivalent) ≥10 mg/d ≥4 weeks</td>
<td>High</td>
<td>Moderate</td>
</tr>
<tr>
<td>Prednisone (or equivalent) &lt;10 mg/d ≥4 weeks</td>
<td>Moderate</td>
<td>Low</td>
</tr>
<tr>
<td>Prednisone (or equivalent) &lt;1 week</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Antimetabolites (e.g. AZA/6-MP or methotrexate)</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Intra-articular corticosteroid injections</td>
<td>Low</td>
<td>Low</td>
</tr>
</tbody>
</table>

AZA: azathioprine; HCC: hepatocellular carcinoma; MP: mercaptopurine; TACE: transarterial chemoembolisation; TNF: tumour necrosis factor.
CLINICAL PRACTICE GUIDELINES

Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020)

Manuel Rodriguez, Maria Buti, Rafael Esteban, Sabela Lens, Martín Prieto, Emilio Suárez, Javier García-Samaniego